Saxenda 3ml Liraglutide Injection Pen

- Bulk Discount From 5 PCS
- Get 5% extra discount by using WISE or Bank Transfer

Saxenda (liraglutide 3ml injection pen) is an prescription medication for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions. Clinical trials demonstrate 56% of patients achieved ≥5% weight loss at 56 weeks when combined with lifestyle changes, with an average 8% body weight reduction. As a GLP-1 receptor agonist, it suppresses appetite by delaying gastric emptying by 31% and enhances satiety, while improving metabolic health markers like HbA1c (-0.6%) and systolic blood pressure (-2.8mmHg).

$108.00

Quantity discounts
Quantity Discount Price
5-93%$104.76
10-195%$102.60
20-Unlimited8%$99.36

Saxenda 3ml Liraglutide Injection Pen

Saxenda (liraglutide 6 mg/ml) is an prescription medication for chronic weight management. Clinical trials demonstrate that 56% of patients achieved ≥5% weight loss at 56 weeks when combined with lifestyle modifications. The 3ml pre-filled pen delivers 18mg liraglutide through easy-to-use multidose injections, working as a GLP-1 receptor agonist to regulate appetite and calorie intake.

Clinically Proven Efficacy

Average 8% body weight reduction observed in clinical studies over 12 months.

Appetite Regulation

Delays gastric emptying by 31% and increases satiety signals.

Metabolic Benefits

Improves HbA1c by 0.6% and systolic BP by 2.8mmHg in obese patients.

Mechanism of Action
  • GLP-1 receptor agonist: 97% amino acid sequence homology with human GLP-1
  • Reduces hunger through hypothalamic appetite nter modulation
  • Slows gastric emptying rate by 20-30% post-meal
  • Enhances first-phase insulin response by up to 118%
  • Packaging Details

    Active Ingredient: Liraglutide 6 mg/ml (18mg per 3ml pen)

    Excipients: Sodium phosphate dibasic dihydrate, propylene glycol, phenol

    Storage: Unopened: 2-8°C; In-use: ≤30°C for ≤30 days

    Clinical Protocol
    Administration

    Subcutaneous injection in abdomen, thigh, or upper arm. Rotate sites.

    Dose Escalation

    Week 1-4: 0.6mg→1.2mg→1.8mg→2.4mg→3.0mg (weekly increments)

    Monitoring

    Assess weight loss at 16 weeks: discontinue if <4% baseline loss.

    Important Safety Information

    *Individual results may vary: Weight loss outcomes depend on metabolic factors and compliance.

    Contraindicated in pregnancy, thyroid cancer history, or multiple endocrine neoplasia.

    Requires prescription and medical supervision. Report adverse reactions to healthcare provider immediately.

    0 reviews
    0
    0
    0
    0
    0

    There are no reviews yet.

    Be the first to review “Saxenda 3ml Liraglutide Injection Pen”

    Your email address will not be published. Required fields are marked *

    Interested in Wholesale?

    Contact Us Now

    Be The First To Know About Wholesale, Exclusive Sales & More

    Interested in Wholesale?

    Contact Us Now

    Be The First To Know About Wholesale, Exclusive Sales & More